Optimizing the Post-CAR T Monitoring Period

Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director at Division of HMCT/University of Kansas Medical Center, shared a paper by Nausheen Ahmed et al on X:

“Out in press by Nausheen Ahmed and colleagues for ASH. Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.

• NRM beyond day 28 is largely driven by infection
• New-onset CRS and ICANS is rare after 2 weeks”

Source: Al-Ola A Abdallah/X

Authors: Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R Bishop, Joseph P. McGuirk, Peter A. Riedell

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel